Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rAd5 env C
- Development stage
- Unknown
- Lead developer
- Vaccine Research Center
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
rAd5 env C is a recombinant replication-defective adenovirus serotype 5 (rAd5) vector-based vaccine encoding the envelope glycoprotein (Env) from HIV-1 clade C. It is designed as a prophylactic HIV vaccine to induce immune responses against HIV-1 by delivering the gene for the Env protein into host cells, leading to expression of the antigen and stimulation of both humoral and cellular immunity. The vaccine has been studied as part of multiclade regimens in combination with other antigens (Gag/Pol/Env from various clades), but "env C" refers specifically to the component expressing Env from clade C. The primary mechanism involves induction of anti-HIV T-cell and antibody responses targeting the envelope glycoprotein. Developed primarily by VRC/NIAID/NIH, it has been evaluated in multiple phase I/II clinical trials for safety and immunogenicity in healthy adults at risk for HIV infection[4][6][7].
- Other names
- recombinant adenovirus serotype 5 HIV-1 Env clade C vaccinerAd5-HIV (EnvC)AD5HIV-ENVCAD-5HIV-ENVCAD 5HIV-ENVC
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on rAd5 env C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rAd5 env C.